OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 6 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 8 days (1-2 days of FREE language polishing included)
Submission Deadline: October 31, 2023 (Open) Submit Now
Brandon Lucke-Wold, MD, PhD
Department of Neurosurgery, University of Florida, United States
Research interests: traumatic brain injury, neurosurgical simulation, and stroke
Michael J Diaz, MS-1
University of Florida College of Medicine, United States
Research interests: brain injury; neurologic outcomes
About This Topic
Neurosurgery stimulation has emerged as a promising therapy for acquired brain injury and deficit. Currently, the US Food and Drug Administration approves the use of the following neurostimulation therapies: electroconvulsive therapy, deep brain stimulation, vagus nerve stimulation, transcranial magnetic stimulation, spinal cord stimulation, and transcutaneous supraorbital stimulation. Established clinical indications for neurostimulation include a range of disabling movement and treatment-resistant neuropsychiatric disorders. However, recent advances in neurostimulation research have ushered in conversation about its restorative utility for a wider range of human encephalopathies via reconfiguration of dysfunctional circuits, livening new neural networks, and pain control, among other applications. Beyond cognitive and behavioral gain-of-function capabilities, evidence has further suggested a role for neurosurgery stimulation in the managed care of non-pain-associated disease states (e.g., obesity). The diverse collection of articles in this special issue will introduce the OBM Neurobiology readership to novel outcomes and breakthrough discoveries in neurosurgical stimulation. Potential topics include measured outcomes of non-invasive and invasive neurostimulation techniques; current standards of practice in neurostimulation; areas of focused inquiry and innovation in neurostimulation; and the role of brain stimulation in the coordinated care of neurosurgical patients.
neurosurgery stimulation; interdisciplinary care; non-invasive electrical stimulation; stimulation frequency; deep brain stimulation; managed care; cognitive and behavioral deficit
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.